Impact of optimum diabetes care on the safety of fasting in Ramadan in adult patients with type 2 diabetes mellitus on insulin therapy. (April 2019)

• Record Type: Journal Article
• Authors: Bashier, Alaaeldin M.K.; Hussain, Azza Khalifa Bin; Alawadi, Fatheya; Alsayyah, Fatima; Alsaeed, Maryam; Rashid, Fauzia; Abdelgadir, Elamin; Bachet, Fawzi; Abuelkheir, Sona; Elsayed, Mohamed; Hassanein, Mohamed
• Is Part Of: Diabetes research and clinical practice. Volume 150(2019)
• Page Start: 301
• Page End: 307
• Publication Date: 2019-04
• Subjects: Ramadan -- Flash glucose monitoring -- Type 2 diabetes -- Hypoglycemia -- Hyperglycemia -- HbA1c -- Basal insulin -- Intensive insulin therapy; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2019.01.037
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Aim: We aimed at evaluating the safety of fasting Ramadan for insulin treated type 2 diabetes patients by assessing the biochemical, biometric parameters, flash glucose monitoring (FGM) data as compared to pre-Ramadan and hospital admissions with diabetes or non-diabetes conditions. The risks of fasting between those treated with basal insulin vs intensive insulin during Ramadan was also assessed. Methods: We included insulin treated patients with type 2 diabetes and we excluded those with co-morbidities. Patients were provided with Ramadan-focused education, FGM before and during Ramadan and medical advice for treatment adjustment. We measured biologic and biometric data before and after Ramadan. Results: HbA1c reduced from 7.9 ± 1.20 pre-Ramadan to 7.7 ± 1.5% post Ramadan (p = 0.023). Average peak glucose reading was 330.1 ± 79.8 mg/dl before Ramadan improved significantly to reach 289.3 ± 77.7 mg/dl (p = 0.013). Average number of hypoglycemic episodes was higher in intensive insulin group between 1200 and 1800 h (p = 0.028). Conclusion: People with type 2 diabetes treated with insulin who fast Ramadan and who are provided with Ramadan focused patient education, individualized treatment adjustment and FGMS were not at increased safety risks as measured by biochemical, biometric and FGM data.